

Information and consent for the patient support program for specialty drugs

Please fill out this page only if you live outside Quebec.

INFORMATION

The prescription drug that is the object of your request is part of our patient support program. Designed to help you better manage your medical condition, this program provides you with many benefits such as access to professional support from a team of pharmacists. For more information, see the *Prior Authorization Drugs and the Patient Support Program* brochure, available at www.desjardinslifeinsurance.com/PAD.

If your contract includes the program, you may be required to participate.

A healthcare professional from the provider selected by Desjardins Insurance will contact you to let you know the status of your request, to explain how the program works and to direct you to a preferred pharmacy. That professional may also contact your attending physician to get any missing information. The information obtained as a result of this prior authorization request will be sent to the third party and used to process your request. This is why your signature is required.

IMPORTANT

As part of the patient support program, you will be reimbursed for your specialty drug only if you purchase it through the preferred pharmacy network.

CONSENT TO DISCLOSE TO A THIRD PARTY

For the sole purpose of the patient support program, I authorize Desjardins Insurance to disclose to the third party personal information about me, especially my medical information, that is needed for the program. I understand that the third party may share this information with my doctors, pharmacists and other healthcare professionals as part of this program.

This consent also applies to the disclosure of personal information concerning my dependents, insofar as this request involves them.

Last name and first name of the member (PLEASE PRINT)	Contract No.	Certificate No.	
Email address of the member			
Signature of the member		Date	
Last name and first name of the parent or legal guardian (if n	necessary)		
Signature of the parent or legal guardian (if necessary)		Date	

This consent is an integral part of the attached Prior Authorization Request form.



C. P. 3950 Lévis (Québec) G6V 8C6 desjardinslifeinsurance.com/planmember Tel.: 1-844-410-6485

Fax: 1-877-838-2134 418-838-2134

PRIOR AUTHORIZATION REQUEST

ACTEMRA (TOCILIZUMAB)

PLEASE READ THE INSTRUCTIONS ON THE LAST PAGE OF THIS FORM.

Α	PATIENT IDENTIFICATION	ON – To be completed by t	he member.					
	Patient's last and first name		Relationship with member			Patient's date of birth		
				Member	r 🗆 Spouse	Dependent chi	ld YYYYY	MM DD
	Member's last and first nam	ne			Contract No.		Certificate No.	
	No., street, apt. City					Province	Postal code	
	Telephone Nos – Home:		Office:	Exter	nsion:	Email:		
			l information, please indicate			med of the decision:		
	Coordination of benefits:	If the patient has coverag	to the address indicated in the under a private insurance and this form filled out by	plan or is enr			lan, please subm	it the request to this
	Does the patient have drug coverage under a private insurance plan?							
			a copy of the notice of appro			attached to this for	m.	
	PRIVATE PLAN	Specify: Name of the in	surer:		Contract No.	:	Certificate No	:
		No						
			ursement been submitted ur	, ,				
	PROVINCIAL PLAN	= '	a copy of the notice of appro	oval or refusal.	→ □ Copy	attached to this for	m.	
		No – Please explain:	n a patient support program?) Ves [l No.			
	PATIENT SUPPORT	·		tes _] NO			
	PROGRAM	If so – Program name: _ Contact person:			Telephon	e No :		extension:
R1	DECLARATION AND AU	·	IF COLLECTION AND CO	MMUNICAT	· ·			ACCIDION.
	the information deemed necessary to manage my file. The non-exhaustive list of sources from which information may be collected includes healthcare profess and insurance companies; (b) communicate to the said persons or organizations only the personal information about me that is deemed necessary for the purp when necessary use the personal information it may have about me in existing files that are now closed. This authorization is also valid for the collection, use ar of personal information concerning my dependents, insofar as applicable to the claim. A photocopy of this authorization is as valid as the original.					purposes of my file; (c) use and communication		
>	Signature of member:	Signature of member: Date:						
	Last name and first name o	Last name and first name of parent/legal guardian (if applicable):						
	Signature of patient or parent/legal guardian (if applicable):				Date:			
B2	To help us process your cla	ONSENT TO THE COMMUNICATION OF PERSONAL INFORMATION TO A THIRD PARTY o help us process your claim more efficiently, do you authorize Desjardins Insurance to inform the patient support program and the attending physician or the attending hysician's medical team of the reasons for the decision on your prior authorization request?						
>	Signature of member:					Date:		
•	Last name and first name of parent/legal guardian (if applicable):							
	Signature of patient or parent/legal guardian (if applicable): Date:							
С			eted by the attending physic	ian.		Date.		
	Physician's last and first nan	•	eccusy the attending physic		ense No.	Specialty		
	No., street, suite City					l	Province	Postal code
	Telephone No.: Fax No.:							
>	Signature of physician:					Date:		
•	Drug name		Formulation 5	Strength	Dosage	Patient's weight	Scheduled dura	ation of treatment
	Where is the drug administo	Where is the drug administered?						
		Other (please specify): Designing Insurance refers to Designing Financial Security Life Assurance Company						

ATTENDING PHYSICIAN SECTION - Continued Make sure to fill out all sections so we can process the request faster. If any information is missing, we will send the form back to the member. In order to consider any diagnosis not mentioned on this form, we need supporting documents (clinical practice guidelines, clinical studies, etc.) that justify the drug's use in the given context. Diagnosis Polyarticular juvenile idiopathic arthritis Systemic idiopathic arthritis with predominant systemic manifestations Systemic idiopathic arthritis with predominant articular manifestations ☐ Giant cell arteritis Rheumatoid arthritis Other therapeutic indication(s) – Please specify: Information relating to rheumatoid arthritis and polyarticular juvenile idiopathic arthritis Number of joints with active synovitis: -C-reactive protein value: _ _ mg/L Erythrocyte sedimentation rate value: ___ mm/hr Please provide at least one of the following pieces of information: Presence of a positive rheumatoid factor: Yes □No Yes □No Presence of radiological erosions: Health Assessment Questionnaire (HAQ) result: Information relating to giant cell arteritis Date of the most recent disease flare: □No Will the treatment be administered as adjunctive therapy to corticosteroids in decreasing doses? Yes Information relating to systemic idiopathic arthritis with articular or systemic manifestations Number of joints with active synovitis: . C-reactive protein value: Erythrocyte sedimentation rate value: ___ mg/L Does the patient show sign of chronic inflammation (anemia, thrombocytosis, leukocytosis)? Yes □No Does the patient show the following conditions? Persistance of fever episodes (> 38°C) Since: Typical skin rash Adenomegaly, hepatomegaly or splenomegaly Lymphadenopathy (cervical, axillary, inguinal) Serous inflammation or effusion PRIOR MEDICATION OR TREATMENT Has the patient ever used medication or received treatment for this medical condition? \square Yes \square No If not, please explain: If so, please list any medication already used or any treatment already received for this medical condition: MEDICATION OR TREATMENT NAME OUTCOME TREATMENT PERIOD From: Name: Inefficiency Intolerance Contraindication Dose: Specify: To: MM DD From: Name: Inefficiency Intolerance Contraindication Dose: Specify: To: MM DD From: Name: Inefficiency Intolerance Contraindication Dose: Specify: To: MM DD From: Name: Inefficiency Intolerance Contraindication MM DD Dose: Specify: To: PRESCRIPTION RENEWAL Please provide objective data that shows a satisfactory clinical or biological response:

	Before treatment	After treatment
Number of joints with active synovitis		
CHAQ score		
C-reactive protein level		
Sedimentation rate		
Physician's global assessment (visual analogue scale)		
Patient's global assessment (visual analogue scale)		

INSTRUCTIONS - HOW TO COMPLETE AND RETURN THIS FORM

- 1. Complete sections A and B.
- 2. Ask your physician to complete section C. The member is responsible for assuming any costs incurred to complete this form or to obtain additional information.
- 3. To obtain a reimbursement once the drug has been approved, please use your payment card at the pharmacy or submit your original receipts by mail. Eligible drugs must be dispensed by a pharmacist or a physician, if there is no pharmacist.

4. Send form: • by fax: Desiardins Insurance

Group Insurance, Health Claims,

• by mail: Desjardins Insurance Group Insurance, Health Claims

C. P. 3950, Lévis (Québec) G6V 8C6 418-838-2134 or 1-877-838-2134 (toll-free)

Under its prior authorization program, Desjardins Insurance authorizes the reimbursement of certain drugs that meet criteria that are based, in particular, on clinical practice guidelines and recommendations issued by health technology assessment organizations. The drug will be eligible for reimbursement if it meets the insurer's criteria, if it's not administered in a hospital and if it's not eligible under a government program. If the information on your form is complete, your request will normally be processed within 5 business days.

When the request form is received, it will be assessed in the strictest confidence. In some situations, additional diagnostic or clinical information may be required.

If the treatment continues beyond the authorized period, you will be asked to submit a new request form and provide information that justifies the extension of treatment. If you have a payment card, your pharmacist will be advised that the authorization period is coming to an end. The insurance must be in force and the patient still covered on the date expenses are incurred. This prior authorization is subject to change if, at the time expenses are incurred, the contract has been modified.

When Desjardins Insurance declines a prior authorization request, it is because we need to uphold conditions set out in the contract. It does not mean we are questioning the physician's opinion. If you have any questions, please contact our Customer Contact Centre at the number indicated on page 1 of this form.